GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reunion Neuroscience Inc (TSX:REUN) » Definitions » Return-on-Tangible-Equity

Reunion Neuroscience (TSX:REUN) Return-on-Tangible-Equity : -108.18% (As of Mar. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Reunion Neuroscience Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Reunion Neuroscience's annualized net income for the quarter that ended in Mar. 2023 was C$-25.97 Mil. Reunion Neuroscience's average shareholder tangible equity for the quarter that ended in Mar. 2023 was C$24.01 Mil. Therefore, Reunion Neuroscience's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2023 was -108.18%.

The historical rank and industry rank for Reunion Neuroscience's Return-on-Tangible-Equity or its related term are showing as below:

TSX:REUN's Return-on-Tangible-Equity is not ranked *
in the Biotechnology industry.
Industry Median: -48.28
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

Reunion Neuroscience Return-on-Tangible-Equity Historical Data

The historical data trend for Reunion Neuroscience's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reunion Neuroscience Return-on-Tangible-Equity Chart

Reunion Neuroscience Annual Data
Trend Mar20 Mar21 Mar22 Mar23
Return-on-Tangible-Equity
-25.51 -37.46 -60.90 -110.50

Reunion Neuroscience Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -78.30 -89.85 -140.56 -153.39 -108.18

Competitive Comparison of Reunion Neuroscience's Return-on-Tangible-Equity

For the Biotechnology subindustry, Reunion Neuroscience's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Reunion Neuroscience's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Reunion Neuroscience's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Reunion Neuroscience's Return-on-Tangible-Equity falls into.



Reunion Neuroscience Return-on-Tangible-Equity Calculation

Reunion Neuroscience's annualized Return-on-Tangible-Equity for the fiscal year that ended in Mar. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Mar. 2023 )  (A: Mar. 2022 )(A: Mar. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Mar. 2023 )  (A: Mar. 2022 )(A: Mar. 2023 )
=-48.493/( (66.476+21.295 )/ 2 )
=-48.493/43.8855
=-110.50 %

Reunion Neuroscience's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2023 )  (Q: Dec. 2022 )(Q: Mar. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2023 )  (Q: Dec. 2022 )(Q: Mar. 2023 )
=-25.968/( (26.715+21.295)/ 2 )
=-25.968/24.005
=-108.18 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Reunion Neuroscience  (TSX:REUN) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Reunion Neuroscience Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Reunion Neuroscience's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Reunion Neuroscience (TSX:REUN) Business Description

Traded in Other Exchanges
N/A
Address
30 Duncan Street, Lower North Suite, Toronto, ON, CAN, M5V 2C3
Reunion Neuroscience Inc is engaged in novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company's asset, RE-104 (previously known as FT-104), is a proprietary, novel psychedelic drug being developed for post-partum and treatment-resistant depression as a potential fast-acting antidepressant with durable efficacy.